<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82638">
  <stage>Registered</stage>
  <submitdate>26/02/2008</submitdate>
  <approvaldate>9/04/2008</approvaldate>
  <actrnumber>ACTRN12608000177358</actrnumber>
  <trial_identification>
    <studytitle>An open label study to examine the characteristics of Human Immunodeficiency Virus (HIV) decay following introduction of combination antiretroviral therapy including raltegravir during primary and chronic HIV infection</studytitle>
    <scientifictitle>An open label study to examine the characteristics of HIV decay following introduction of combination antiretroviral therapy including raltegravir during primary and chronic HIV infection</scientifictitle>
    <utrn />
    <trialacronym>PINT01</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Primary HIV (acute or early)</healthcondition>
    <healthcondition>Chronic HIV infection</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Acquired immune deficiency syndrome (AIDS / HIV)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study is an open-label study of 1-year duration. This study will be conducted at 5 study sites in Sydney, Australia. Sixteen participants will be recruited comprising 8 participants diagnosed with primary HIV infection (Cohort A) and 8 individuals with chronic HIV infection (Cohort B). All patients must be antiretroviral therapy (ART) na√Øve and will commence a regimen of combination ART consisting of tenofovir disoproxil fumarate and emtricitabine (TDF/FTC; Truvada) plus the integrase inhibitor, raltegravir.  Subjects will be followed for one year with intensive quantification of both plasma Ribonucleic acid (RNA) and cell associated Deoxyribonucleic acid (DNA) viral species. Truvada (FTC 200mg + TDF 300mg) once daily plus Isentress (raltegravir 400mg) twice daily.</interventions>
    <comparator>No control group. No randomized trial. Pilot study</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Viral RNA decay characteristics in plasma as determined by an ultrasensitive HIV RNA Polymerase chain reaction (PCR) with a limit of detection of 0.4 copies/ml.</outcome>
      <timepoint>Plasma viral RNA will be measured twice a week for the first 4 weeks then at two weekly intervals until Week 12 then at four weekly intervals until Week 24, then at 8 weekly intervals until Week 40 with a final visit at Week 52. The decay curves will be compared between the two treatment groups.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the absolute levels and decay characteristics of:
1. Total HIV DNA in peripheral blood mononuclear cells (PBMC).</outcome>
      <timepoint>Day 0, week 12 24 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the absolute levels and decay characteristics of:
2. Total HIV DNA in CD4+ T lymphocytes.</outcome>
      <timepoint>Day 0, week 12 24 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the absolute levels and decay characteristics of:
3.	Integrated HIV DNA in PBMC and CD4+ T lymphocytes (Week 0, 12, 24 and 52).</outcome>
      <timepoint>Screening, day 0, week 0.5 1 1.5 2 1.5 3 3.5 4 6 8 10 12 16 20 24 32 40 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4.	Episomal HIV DNA in PBMC and CD4+ T lymphocytes.</outcome>
      <timepoint>Screening, day 0, week 0.5 1 1.5 2 1.5 3 3.5 4 6 8 10 12 16 20 24 32 40 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5.	Total DNA, integrated and episomal DNA in resting CD4+ T cells (CD3+, CD4+, CD69-, CD25-, HLADR-).</outcome>
      <timepoint>Screening, day 0, week 0.5 1 1.5 2 1.5 3 3.5 4 6 8 10 12 16 20 24 32 40 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6.	Total HIV DNA in CD4+ T lymphocytes in lymphoid tissue. (Week 0 and 52)</outcome>
      <timepoint>Screening - day 0, week 40 - week 52</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age at least 18 years. 
Provision of written, informed consent. 
Screening plasma HIV RNA &gt; 10,000 copies/mL.
Screening CD4+ T lymphocyte count &gt; 100 x 106/L.
No previous antiretroviral therapy.
Haemoglobin &gt; 115 g/L (female) or &gt; 130 g/L (male).
Absolute neutrophil count &gt; 1 x 109/L.
Platelet count &gt; 100 x 109/L
Serum bilirubin &lt; 1.5 x upper limit normal (ULN). 
Serum alkaline phosphatase &lt; 3 X ULN.
Serum aspartate aminotransferase (AST) &lt; 3 X ULN.
Serum alanine aminotransferase (ALT) &lt; 3 X ULN. 
Creatinine clearance &gt; 50mL/min 
    (Creatinine clearance (mL/min) =140 - age x weight                  
                                                             creatinine Multiply the result by 1.2 for men).

Cohort A: Primary HIV infection:
Documented acute or early infection diagnosed by: 

Acute infection:  
&lt; 3 bands on Western Blot and any one of: 
i.  positive p24 antigen 
ii. positive proviral DNA 

Early infection: 
i. Positive detuned or B + E + D enzyme linked immuno-sorbent assay (BED ELISA)  result 
OR
ii. Previously negative serology within 6 months of confirmed positive serology.

Cohort B: Chronic HIV infection:
Documented HIV-infection of at least 12 months duration.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy or breastfeeding.
Receipt of investigational products within 1 month of study entry.
Receipt of any of the following within 6 months of study entry:
o interferon a or ? 
o oral corticosteroids (inhaled or topical corticosteroids are permitted)
o cylcosporin
o alkylating agents
o other immunosuppressive agents
o rifampin
o phenytoin 
o phenobarbitol
Documented genotypic (IAS 2007) resistance to tenofovir or emtricitabine from any HIV drug resistance test.
Any medications contraindicated with Truvada or raltegravir.
Significant intercurrent illnesses apart from HIV infection such as viral hepatitis (diagnosed by core hepatitis B antigen and/or positive hepatitis B PCR or positive hepatitis C PCR) or any other condition which in the opinion of the investigator would compromise participation in the study.
History of non-traumatic osteoporotic fracture.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>15/03/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>16</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2010</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>National Centre in HIV Epidemiology and Clinical Research</primarysponsorname>
    <primarysponsoraddress>Level 2
376 Victoria St
Darlinghurst  NSW  2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>National Centre in HIV Epidemiology and Clinical Research (NCHECR), University of New South Wales (UNSW)</fundingname>
      <fundingaddress>Level 2
376 Victoria St
Darlinghurst  NSW  2010</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Merck, Sharp and Dohme</fundingname>
      <fundingaddress>54-68 Ferndell Street, South Granville  NSW 2142
PO Box 79, Granville NSW 2142</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>An open label study to examine the characteristics of HIV decay following
introduction of combination antiretroviral therapy including raltegravir during
primary and chronic HIV infection.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>St Vincent's Hospital,
Victoria Street
Darlinghurst NSW 2010</ethicaddress>
      <ethicapprovaldate>17/12/2007</ethicapprovaldate>
      <hrec>07/SVH/89</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Anthony Kelleher</name>
      <address>NCHECR Level 2
376 Victoria St
Darlinghurst  NSW  2010</address>
      <phone>02 9385 0900</phone>
      <fax />
      <email>tkelleher@cfi.unsw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Christoph Boesecke</name>
      <address>NCHECR Level 2
376 Victoria St
Darlinghurst  NSW  2010</address>
      <phone>02 9385 0900</phone>
      <fax />
      <email>cboesecke@nchecr.unsw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Margaret Allan</name>
      <address>NCHECR Level 2
376 Victoria St
Darlinghurst  NSW  2010</address>
      <phone />
      <fax />
      <email>cboesecke@nchecr.unsw.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>